Emerging PET Imaging Agents and Targeted Radioligand Therapy: A Review of Clinical Applications and Trials.

ABSTRACT: Targeted radioligand therapy (RLT) is an emerging field in anticancer therapeutics with great potential across tumor types and stages of disease. While much progress has focused on agents targeting somatostatin receptors and prostate-specific membrane antigen (PSMA), the same advanced radioconjugation methods and molecular targeting have spurred the development of numerous theranostic combinations for other targets. A number of the most promising agents have progressed to clinical trials and are poised to change the landscape of positron emission tomography (PET) imaging. Here, we present recent data on some of the most important emerging molecular targeted agents with their exemplar clinical images, including agents targeting fibroblast activation protein (FAP), hypoxia markers, gastrin-r

SUBMITTER: Palihati M 

PROVIDER: S-EPMC12390037 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature